Desensitization to thalidomide in a patient with multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 8, Issue 3, 2008, Pages 176-178

  Nucera, Eleonora ^a   Schiavino, Domenico ^a   Hohaus, Stefan ^a   Leone, Giuseppe ^a   Buonomo, Alessandro ^a   Lombardo, Carla ^a   Patriarca, Giampiero ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Nonallergic drug hypersensitivity; Oral tolerance induction; Patch tests

Indexed keywords

ALLOPURINOL; ATENOLOL; BISPHOSPHONIC ACID DERIVATIVE; CHLORPHENIRAMINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ENOXAPARIN; ERYTHROPOIETIN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; INSULIN; LACIDIPINE; LORATADINE; MELPHALAN; OMEPRAZOLE; PREDNISONE; THALIDOMIDE; IMMUNOSUPPRESSIVE AGENT;

AGED; ALLERGY TEST; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CASE REPORT; DESENSITIZATION; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; HYDRATION; HYPERCALCEMIA; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; LEUKEMIA REMISSION; MACULOPAPULAR RASH; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATCH TEST; PROVOCATION TEST; SKIN TEST; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; METHODOLOGY; REMISSION;

AGED; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; REMISSION INDUCTION; THALIDOMIDE;

EID: 49649113199     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.022     Document Type: Article

References (22)

1. Shingal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-71.
2. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91:4082-5.
3. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
4. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Italian Multiple Myeloma Network, GIMEMA. Lancet 2006; 367:825-31.
5. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Bologna 2002 study. Blood 2005; 106:35-9.
6. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431-6.
7. Richardson P, Anderson K. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma. J Clin Oncol 2006; 24:334-6.
8. Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117:508-15.
9. Hall VC, El-Azhary RA, Bouwhuis S, et al. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol 2003; 48:548-52.
10. Horowitz SB, Stirling AL. Thalidomide-induced toxic epidermal necrolysis. Pharmacotherapy 1999; 19:1177-80.
11. Nijsten T, Meuleman L, Schroyens W, et al. Thalidomide-induced morbilliform rush: diagnosis and continuation of therapy, premedicated with methylprednisolone. Dermatology 2002; 204:365-7.
12. Brockow K, Romano A, Blanca M, et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57:45-51.
13. Marks JG Jr, Belsito DV, De Leo VA, et al. American Contact Dermatitis Group patch test results 1996-1998. Arch Dermatol 2000; 136:272-3.
14. Patriarca G, Rossi M, Schiavino D, et al. Rush desensitization in heparin hypersensitivity: a case report. Allergy 1994; 49:292-4.
15. Patriarca G, Schiavino D, Nucera E, et al. Successful desensitization of a child with desferrioxamine hypersensitivity. J Investig Allergol Clin Immunol 1995; 5:294-5.
16. Nucera E, Schiavino D, Buonomo A, et al. Tolerance induction to cotrimoxazole. Allergy 2000; 55:681-2.
17. Nucera E, Roncallo C, Masini L, et al. Successful tolerance induction to spiramycin in pregnancy. Scand J Infect Dis 2002; 34:550-1.
18. Nucera E, Schiavino D, Merendino E, et al. Successful fluorescein desensitization. Allergy 2003; 58:458.
19. Nucera E, Schiavino D, Pollastrini E, et al. Tolerance induction to rofecoxib in a patient with Bartter's syndrome. Allergy 2004; 59:788-9.
20. Sullivan TJ. Drug allergy. In: Middleton E Jr, Redd CE, Ellis EF, et al (eds). Allergy: Principles and Practice. Vol II. 4th Ed. St. Louis, MO: Mosby-Yearbook Inc; 1993:1726-46.
21. Kepley CL. Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk proteins level. Int Arch Allergy Immunol 2005; 138:29-39.
22. Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol 2005; 94:575-80.